NASDAQ:ALLK

Allakos - ALLK Stock Forecast, Price & News

$6.47

-0.50 (-7.17%)

(As of 10/7/2022 05:28 PM ET)

Add

Compare

Today's Range: $6.46
▼
$6.96
50-Day Range: $3.14
▼
$6.97
52-Week Range: $2.54
▼
$11.73

Volume: 695,813 shs
Average Volume: 1.66 million shs
Market Capitalization: $354.84 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $66.80

Allakos MarketRank™ Forecast

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 934.1% Upside
$66.80 Price Target
Short Interest: Bearish
7.33% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.86
Upright™ Environmental Score
News Sentiment: 1.60
Based on 4 Articles This Week
Insider Trading: Acquiring Shares
$20 M Bought Last Quarter
Proj. Earnings Growth: Growing
From ($6.05) to ($2.95) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.74 out of 5 stars

Medical Sector

81st out of 1,075 stocks

Pharmaceutical Preparations Industry

27th out of 537 stocks

3.0

Analyst's Opinion

Consensus Rating
Allakos has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 2 buy ratings, 7 hold ratings, and 2 sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $66.80, Allakos has a forecasted upside of 934.1% from its current price of $6.46.
Amount of Analyst Coverage
Allakos has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
7.33% of the float of Allakos has been sold short.
Short Interest Ratio / Days to Cover
Allakos has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Allakos has recently increased by 54.19%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Allakos does not currently pay a dividend.
Dividend Growth
Allakos does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Allakos has received a 74.59% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physiological diseases " and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Allakos is -0.86.

4.2

News and Social Media Coverage

News Sentiment
Allakos has a news sentiment score of 1.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Allakos this week, compared to 3 articles on an average week.
Search Interest
26 people have searched for ALLK on MarketBeat in the last 30 days. This is an increase of 13% compared to the previous 30 days.
MarketBeat Follows
7 people have added Allakos to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days.

5.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Allakos insiders have bought more of their company's stock than they have sold. Specifically, they have bought $19,999,680.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
33.25% of the stock of Allakos is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
66.67% of the stock of Allakos is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Allakos are expected to grow in the coming year, from ($6.05) to ($2.95) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Allakos is -0.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Allakos is -0.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Allakos has a P/B Ratio of 0.79. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Allakos (NASDAQ:ALLK) Stock

Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. The company was incorporated in 2012 and is headquartered in Redwood City, California.

Receive ALLK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allakos and its competitors with MarketBeat's FREE daily newsletter.

ALLK Stock News Headlines

October 7, 2022 | americanbankingnews.com

Allakos Inc. (NASDAQ:ALLK) Receives $44.75 Consensus PT from Brokerages

October 7, 2022 | americanbankingnews.com

Allakos Inc. (NASDAQ:ALLK) Receives Average Rating of "Hold" from Analysts

September 27, 2022 | marketwatch.com

Allakos Shares Rise After Co. Says Chmn, Director Buy Shares - MarketWatch

September 26, 2022 | uk.investing.com

Adobe And 2 Other Stock Insiders Are Buying By Benzinga - Investing.com UK

September 24, 2022 | finance.yahoo.com

After losing 95% in the past year, Allakos Inc. (NASDAQ:ALLK) institutional owners must be relieved by the recent gain

September 21, 2022 | investorplace.com

Why Is Allakos (ALLK) Stock Soaring 25% Today? - InvestorPlace

September 20, 2022 | benzinga.com

Why Allakos Shares Are Rising Sharply - Allakos (NASDAQ:ALLK) - Benzinga

September 19, 2022 | seekingalpha.com

IceCure Medical, Allakos top healthcare gainers; Virios Therapeutics lead losers' pack - Seeking Alpha

September 19, 2022 | uk.investing.com

Why Allakos Shares Are Rising Sharply By Benzinga - Investing.com UK

September 19, 2022 | investorplace.com

Why Is Allakos (ALLK) Stock Soaring 25% Today?

September 19, 2022 | marketwatch.com

Allakos Shares Surge After Public Offering >ALLK - MarketWatch

September 19, 2022 | seekingalpha.com

Allakos prices ~$150M underwritten offering - Seeking Alpha

September 19, 2022 | finance.yahoo.com

Allakos Announces Pricing of $150 Million Underwritten Offering of Common Stock

September 12, 2022 | finance.yahoo.com

Allakos Announces Initiation of Phase 2b Clinical Trial of Subcutaneous Lirentelimab in Chronic Spontaneous Urticaria (CSU)

September 11, 2022 | seekingalpha.com

Allakos falls as lead asset offers mixed results in late-stage trial

September 9, 2022 | seekingalpha.com

ALLK stock falls as lead asset offers mixed results in late-stage trial (NASDAQ:ALLK) - Seeking Alpha

September 9, 2022 | benzinga.com

Allakos (NASDAQ:ALLK) – Allakos shares are trading lower after the company announced topline Phase 3 data - Benzinga

September 9, 2022 | streetinsider.com

Pre-Open Movers: DocuSign, Zscaler Jumps Post EPS; Allakos Falls on Drug Data - StreetInsider.com

September 9, 2022 | benzinga.com

Allakos (NASDAQ:ALLK) – Allakos Announces Topline Phase 3 Data From EoDyssey Study In Patients With Eosin - Benzinga

September 9, 2022 | finance.yahoo.com

After Disappointing Data, Allakos Discontinues Work On Lirentelimab In Eosinophilic Gastrointestinal Diseases

September 9, 2022 | streetinsider.com

Cowen on Allakos Inc. (ALLK): 'EoDyssey Miss Was Anticipated' - StreetInsider.com

September 9, 2022 | marketwatch.com

Allakos Shares Slip Premarket After Lirentelimab Study Update >ALLK - MarketWatch

September 9, 2022 | benzinga.com

Allakos (NASDAQ:ALLK) – After Disappointing Data, Allakos Discontinues Work On Lirentelimab In Eosinophil - Benzinga

September 9, 2022 | globenewswire.com

Allakos Announces Topline Phase 3 Data from the EoDyssey Study in Patients with Eosinophilic Duodenitis - GlobeNewswire

September 5, 2022 | reuters.com

ALLK.O - Allakos Inc | Stock Price & Latest News | Reuters

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ALLK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allakos and its competitors with MarketBeat's FREE daily newsletter.

ALLK Company Calendar

Last Earnings: 8/04/2022
Today: 10/07/2022
Next Earnings (Estimated): 11/14/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ALLK
CUSIP: N/A
CIK: 1564824
Web: www.allakos.com
Phone: (650) 597-5002
Fax: N/A
Employees: 192
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $66.80
High Stock Price Forecast: $155.00
Low Stock Price Forecast: $13.00
Forecasted Upside/Downside: +932.5%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 11 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($7.39)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-269,860,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -111.03%
Return on Assets: -89.18%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.08
Quick Ratio: 6.08

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $8.20 per share
Price / Book: 0.79

Miscellaneous

Outstanding Shares: 54,844,000
Free Float: 36,608,000
Market Cap: $354.84 million
Optionable: Not Optionable
Beta: 0.46

Key Executives

Dr. Robert Alexander Ph.D. (Age 52)
CEO & Director
Comp: $1.39M

Dr. Adam L. Tomasi Ph.D. (Age 52)
Pres & COO
Comp: $1.06M

Mr. Baird Radford III
Chief Financial Officer

Meg Fitzgerald
Sr. VP, Gen. Counsel, Sec. and Chief Compliance Officer

Dr. Henrik Sandvad Rasmussen (Age 63)
Strategic Advisor

Dr. Craig Paterson M.D.
Chief Medical Officer

Brad Youngblood
Head of Research

Mr. Alan Chang
Director of Medical Affairs & Data Analytics

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ALLK Stock - Frequently Asked Questions

Should I buy or sell Allakos stock right now?: 11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Allakos in the last year. There are currently 2 sell ratings, 7 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ALLK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALLK, but not buy additional shares or sell existing shares.
View ALLK analyst ratings or view top-rated stocks.
What is Allakos' stock price forecast for 2022?: 11 brokers have issued 12 month target prices for Allakos' stock. Their ALLK share price forecasts range from $13.00 to $155.00. On average, they anticipate the company's stock price to reach $66.80 in the next year. This suggests a possible upside of 858.4% from the stock's current price.
View analysts price targets for ALLK or view top-rated stocks among Wall Street analysts.
How have ALLK shares performed in 2022?: Allakos' stock was trading at $9.79 at the beginning of the year. Since then, ALLK stock has decreased by 28.8% and is now trading at $6.97.
View the best growth stocks for 2022 here.
When is Allakos' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our ALLK earnings forecast.
How were Allakos' earnings last quarter?: Allakos Inc. (NASDAQ:ALLK) announced its quarterly earnings results on Thursday, August, 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.86) by $0.05.
What other stocks do shareholders of Allakos own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Allakos investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), Pfizer (PFE), Agios Pharmaceuticals (AGIO), Biohaven (BHVN), bluebird bio (BLUE), Eastman Chemical (EMN), Heron Therapeutics (HRTX), TG Therapeutics (TGTX) and Arbutus Biopharma (ABUS).

When did Allakos IPO?: (ALLK) raised $96 million in an initial public offering on Thursday, July 19th 2018. The company issued 6,000,000 shares at $15.00-$17.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and William Blair was co-manager.
What is Allakos' stock symbol?: Allakos trades on the NASDAQ under the ticker symbol "ALLK."
How do I buy shares of Allakos?: Shares of ALLK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Allakos' stock price today?: One share of ALLK stock can currently be purchased for approximately $6.97.
How much money does Allakos make?: Allakos (NASDAQ:ALLK) has a market capitalization of $382.26 million. The company earns $-269,860,000.00 in net income (profit) each year or ($7.39) on an earnings per share basis.
How many employees does Allakos have?: The company employs 192 workers across the globe.
How can I contact Allakos?: Allakos' mailing address is 975 ISLAND DRIVE SUITE 201, REDWOOD CITY CA, 94065. The official website for the company is www.allakos.com. The company can be reached via phone at (650) 597-5002 or via email at ir@allakos.com.

This page (NASDAQ:ALLK) was last updated on 10/7/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Allakos - ALLK Stock Forecast, Price & News

Allakos MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Allakos (NASDAQ:ALLK) Stock

ALLK Stock News Headlines

ALLK Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

ALLK Stock - Frequently Asked Questions

MarketBeat Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

Overall MarketRank^™